FDA approves 10th indication for Humira

SILVER SPRING, Md. — The Food and Drug Administration has approved AbbVie’s Humira (adalimumab) to treat adults with non-infectious intermediate, posterior and panuveitas, the company announced Friday. Its new indication is the 10th for the drug in the U.S. for immune-meditated diseases.

 

"We are pleased to provide patients with the first FDA-approved non-corticosteroid treatment option for certain types of uveitis, an eye disease that can flare and impact vision,” AbbVie EVP research and development and chief scientific officer Dr. Mike Severino said. "These approvals reflect our ongoing focus on continuing to innovate with HUMIRA to address critical unmet needs of patients living with serious immune-mediated diseases."

 

Humira was first approved in 2003, and has since been approved in more than 90 countries.